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Background: Tuberculosis is the leading cause of death due to bacterial infections worldwide, mainly caused by
Mycobacterium tuberculosis. The antigen 85 complex comprises a set of major secreted proteins of M. tuberculosis,
which are potential biomarkers for diagnostic.
Results: In this work, the first human single chain fragment variable (scFv) antibodies specific for the tuberculosis
biomarker 85 B were selected by phage display from naïve antibody gene libraries (HAL7/8). Produced as scFv-Fc
in mammalian cells, these antibodies were further characterized and analysed for specificity and applicability in
different tuberculosis antigen detection assays. Sandwich detection of recombinant 85 B was successful in
enzyme linked immunosorbent assay (ELISA), lateral flow immunoassay and immunoblot. Whereas detection of
M. tuberculosis cell extracts and culture filtrates was only possible in direct ELISA and immunoblot assays. It was
found that the conformation of 85 B, depending on sample treatment, influenced antigen detection.
Conclusions: Recombinant antibodies, selected by phage display, may be applicable for 85 B detection in various
assays. These antibodies are candidates for the development of future point of care tuberculosis diagnostic kits. Using
85 B as a biomarker, the antigen conformation influenced by sample treatment is important.Background
Approximately 8.7 million people worldwide fell ill with
tuberculosis (TB) in 2011 and 1.4 million deaths were
reported [1]. Worldwide TB ranks as the second major
cause of death from an infectious disease. One third of
the world population is estimated to be infected with M.
tuberculosis (Mtb), yet they remain asymptomatic. This
is defined as latent TB infection (LTBI) [2]. Only 66% of
the TB-cases worldwide are correctly diagnosed [1]. The
gold standard in TB diagnosis remains the preparation of
liquid cultures in selective media from sputum or tissue/
body fluid specimens [3]. This is followed by further Mtb
specific tests or drug susceptibility testing (i.e. nucleic acid
amplification tests such as the Gene Xpert MTB/RIF [4]).
Diagnosis of TB in most low- and middle-income coun-
tries continues to rely on sputum smear microscopy for
acid-fast bacilli (Ziel-Neelsen stain) [1]. This technique de-
tects only 40 – 60% of pulmonary TB cases and is not able* Correspondence: m.hust@tu-bs.de
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unless otherwise stated.to differentiate between Mtb and other ubiquitous myco-
bacteria [5,6]. This is less sensitive in children, HIV co-
infected patients and in patients with extrapulmonary TB
[7,8]. The diagnosis of TB in developing countries is
limited by equipment and infrastructure [1]. Therefore, in
these countries, a simple diagnostic tool without the need
for sophisticated instruments is needed. Accuracy, simpli-
city, affordability and technical robustness are important
factors for a point of care (POC) TB-test. The main ad-
vantage of this is a rapid diagnosis, which allows initiation
of treatment while the patient is still accessible [9]. Several
anti-tuberculosis antibody detection systems are available.
However the WHO recommended against the use of these
assays because of their lack of sensitivity and specificity
[10]. Direct detection of Mtb antigens in human speci-
mens would allow specific diagnosis of active TB to be
made, independent of the host’s immune response. Fur-
thermore, the use of specific antibodies to Mtb antigens in
a lateral flow immuno assay (LFIA) would potentially pro-
vide a rapid POC test in a cost effective, easy-to-use
format. Potential target antigens for POC TB-detection in
human samples should be selected by the followingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ence in the extracellular environment or on the mycobac-
terial cell wall, and resistance to degradation by host
enzymes [11]. The 85 complex is a major secretion prod-
uct of Mtb [12,13] which comprises three variant 85 pro-
teins (A, B and C) that are encoded by three different
genes (fbpA, fbpB and fbpC2, [14]). Antigens 85 A, 85 B
and 85 C possess mycoyltransferase activity and are
involved in the formation of trehalose monomycolate
(TMM) and trehalose dimycolate (TDM), which are com-
ponents of the mycobacterial cell wall [15,16]. Besides the
85 complex there is another 85 protein, known as 85 D or
FbpC1. 85 D shows structural similarity to the 85 complex
proteins, yet does not possess mycoyltransferase activity
[15] and its function remains unknown. Disruption of
fbpA results in the inability of Mtb to replicate within
macrophages, indicating a key role in virulence [17]. Fur-
thermore, it was shown that 85 complex proteins interact
with gelatine-binding sites of human fibronectin, enhan-
cing complement-mediated phagocytosis by macrophages
[18-20]. Antibodies specific for only one of the 85 proteins
would allow for further investigation of their individual
roles in the pathogenesis of TB. However only antibodies
cross reacting with all other 85 complex proteins have
been reported so far [21-23].
The presence of the 85 complex was demonstrated in
human serum [24], urine [20], cerebrospinal fluid [25]
and sputum [26] of TB infected individuals. This makes
it a prominent marker for TB. Although other mycobac-
teria express similar 85 complex proteins, these antigens
could be used as TB markers in combination with other
antigens to enhance specificity.
For the future development of diagnostic assays, recom-
binant antibodies generated by phage display are an alter-
native to polyclonal and monoclonal antibodies [27-32].
Naïve antibody libraries allow generation of antibodies to
epitopes which are not recognized by any immune system.
In addition, recombinant human antibodies could be used
in therapeutic applications. In this work, single chain Fv
(scFv) were isolated from a human naïve antibody gene li-
brary using phage display [33] and produced as scFv-Fc








Abbreviations: HV variable (V) gene segment of the heavy chain, D diversity gene se
segment of the light chain, LJ joining gene segment of the light chain.and analysed for their suitability in an antigen detection
assay targeting Mtb 85 B.
Results
Selection of human antibodies against 85 B
For antibody selection, panning was performed on immobi-
lized 85 B followed by a screening ELISA using soluble scFv
(see Additional file 1: Figure S1). Finally, five unique scFv
were confirmed by DNA sequencing. The corresponding
human germline sequences according to VBASE2 [35] are
displayed in Table 1. All α-85 B antibodies contain a vari-
able gene segment of the heavy chain (HV) of subfamily
VH3. Four binders have a lambda light chain (VLλ) and one
has a kappa light chain (VLκ). All VLλ clones have a joining
segment of the heavy chain (HJ) of subfamily J4, a joining
segment of the light chain (LJ) of subfamily J3, and a vari-
able gene segment of the heavy chain (HV) of subfamily
VH3 gene 30.
Cloning and production of scFv-Fc (Yumabs)
The scFv were subcloned into pCSE2.5-hIgG1-Fc-XP [34],
produced in 50 mL scale and purified from the culture
supernatant via Protein A. The purified scFv-Fc (Yumabs)
were analysed by SDS-PAGE, silver staining, α-human
IgG(Fc) immunoblot and reducing gel analysis via Tape
Station. No degradation was detected (data not shown).
The purity of the obtained antibody preparations was de-
termined to 93.4 – 96.9%.
Validation of antigen binding
The antigen binding of the Yumabs was analysed by titra-
tion ELISA (Figure 1A). The antigen binding was con-
firmed for all Yumabs. Antigen detection limits of the α-85
B scFv-Fc were determined by antigen titration ELISA
(Figure 1B). About 5 ng/mL were detected by MFU50-
C10, ~ 10 ng/mL by MFU50-A10 and MFU50-E2, and ~
30 ng/mL by MFU50-D4 and MFU50-D7.
Epitope mapping
To determine whether the antibodies bind to linear or
conformational epitopes, the α-85 B scFv-Fc were ana-








gment, HJ joining (J) gene segment of the heavy chain, LV variable gene
Figure 1 Analysis of antigen binding. A) Antibody titration and B) antigen titration in ELISA with α-85 B scFv-Fc. A) Dilution series of scFv-Fc were
used for detection of directly coated antigen (85 B) or BSA (negative control). Detection of bound scFv-Fc with goat α-human IgG(Fc)-HRP and
development with TMB. B) Different dilutions of antigen (85 B) were directly coated to the wells. Antigen detection with a scFv-Fc concentration of half
maximal saturation. Detection of bound scFv-Fc with goat α-human IgG(Fc)-HRP, development with TMB. Negative control BSA A450 = 0.05.
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ping of the α-85 B scFv-Fc was carried out on PepSpot
membranes (Figure 2A). Through the overlap of the pep-
tide sequences the epitopes were determined (Figure 2B).
The crystal structure of antigen 85 B was determined by
Anderson et al. [36] and the epitopes were visualized on
the 3D structure of the antigen (Figure 2C). The dis-
tance between epitope regions “AFSRPGPLV(EYL)” and
“SPAVYL” was computed to ~ 2.5 nm, between “SPAVYL”
and “SSDPAWERN(DPT)” to ~ 4 nm and between
“SSDPAWERN(DPT)” and “AFSRPGPLV(EYL)” to ~ 5 nm.
Considering the width of an antibody (~4 nm, [37]),
sandwich detection was likely targeting epitopes on
different sites of the antigen.
Cross reactions
Sequence comparison of the epitopes of the α-85 B anti-
bodies with corresponding sequences of the other 85 com-
plex antigens provided information about possible crossreactions (Table 2). The complete epitope “AFSRPGPLV
(EYL)” is present in antigen 85 A and 85 C, but not in 85
D. Homologous regions of the epitopes “SPAVYL” and
“SSDPAWERN(DPT)” can be found in 85 A, C, and D.
Experimental study of 85 complex cross reactivity was car-
ried out by indirect ELISA (Figure 3). MFU50-A10 reacted
with 85 A and 85 D. MFU50-D4 displayed a weak cross
reactivity with 85 A as predicted. MFU50-E2 bound anti-
gen 85 B weakly and showed no cross reactions. MFU50-
D7 reacted weakly with 85 B. No reaction with the other
85 complex antigens was detected. MFU50-C10 was also
not cross reactive. A summary of the expected cross reac-
tions in comparison to determined cross reactions is out-
lined in Table 2.
Detection of 85 B in Mtb cell extracts and culture filtrates
The antibody binding to Mtb/BCG cell extracts and cul-
ture filtrates was analysed by indirect ELISA (Figure 4).
In this assay only MFU50-A10 reacted with Mtb culture
Figure 2 Analysis of the epitope. A) Epitope mapping of α-85 B scFv-Fc with PepSpot membrane, B) Amino acid sequences of PepSpots and
C) 3 D structure of 85 B and α-85 B antibody epitopes. A) Membrane was incubated with respectively 5 μg scFv-Fc, detection of bound scFv-Fc
with goat α-human IgG(Fc)-HRP, development with TMB. Immunostained spots are circled. No cross reaction of the secondary antibody with the
PepSpots was determined (data not shown). B) Amino acid sequences of peptides on 85 B PepSpot membrane. The immunostained spots and
identified epitopes are highlighted. C) 3D structure of antigen 85 B, epitopes of α-85 B antibodies. Pdb1f0n (Resolution 1.9 Å, [36]) was modified
with 3D molecule viewer (Invitrogen). Only protein chain A is shown, atoms are displayed as space filling balls, epitopes are marked in yellow,
distance measurement in red.
Table 2 Cross reactions of α-85 B antibodies with other 85 complex antigens
sequence comparison (corresponding sequences to α-85 B epitopes)
Clone 85 A 85 B 85 C* 85 D Expected cross reaction
MFU50-A10 KEDPAWQRNDPL SSDPAWERNDPT SSDPAWKRNDPM SDPA 85 A, 85 C, 85 D
MFU50-C10 SPALYL SPAVYL PHAVYL PHAVYL 85 A, 85 C, 85 D
MFU50-D4 AFSRPGLPV AFSRPGLPV AFSRPGLPV - 85 A, 85 C
MFU50-D7 AFSRPGLPVEYL AFSRPGLPVEYL AFSRPGLPVEYL - 85 A, 85 C
MFU50-E2 KEDPAWQRN SSDPAWERN SSDPAWKRN SDPA 85 A, 85 C, 85 D
Reaction with 85 complex antigens in ELISA
Clone 85 A 85 B 85 C* 85 D Determined cross reaction
MFU50-A10 Strong Strong - Strong 85 A, 85 D
MFU50-C10 None Strong - None None
MFU50-D4 Weak Strong - None Weak 85 A
MFU50-D7 None Weak - None None
MFU50-E2 None Weak - None None
*Purified antigen 85 C was not available for immunological assays, nevertheless it is listed for completeness of the illustration.
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Figure 3 Cross reactions of α-85 B scFv-Fc with other 85 complex antigens in ELISA. 100 ng of the antigens were directly coated to the
wells. 85 B detection with α-85 B scFv-Fc (using concentrations at half maximal saturation), detection of bound scFv-Fc with goat α-human IgG
(Fc)-HRP, development with TMB.
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bound only to recombinant 85 B. A weak cross reaction
of MFU50-A10 with 7H9 medium was detected.
Development of a sandwich ELISA
Due to the availability of five different antibodies with three
different epitopes on the target antigen a sandwich α-85 B
assay was performed. Therefore MFU50-A10 (epitope
“SSDPAWERNDPT”), MFU50-C10 (epitope “SPAVYL”)
and MFU50-D4 (epitope “AFSRPGLPV”) scFv-Fc were
conjugated to HRP. Sandwich ELISA detection of the
antigen was carried out with MFU50-A10-HRP, MFU50-
C10-HRP or MFU50-D4-HRP as detection antibodies.
Capturing was conducted with corresponding antibodies
recognizing different epitopes (than the detection antibody)Figure 4 Reaction of α-85 B scFv-Fc with Mtb/BCG cell extracts and cu
different samples were directly coated to the well, reaction was determine
scFv-Fc with goat α-human IgG(Fc)-HRP. Development with TMB.on the target (Figure 5A, B, C). Blocking reagent only was
used as a negative control (A450 = 0.02 – 0.05). Sandwich
detection of the recombinant antigen was successful with
all combinations. The antigen detection limit for capturing
with MFU50-A10, MFU50-C10, MFU50-D4 or MFU50-
D7 was determined to ~ 10 ng/mL, independent from the
detection antibody. Capturing with MFU50-E2 resulted in
a detection limit of ~ 25 ng/mL. The most suitable com-
bination was obtained with MFU50-A10 as the capture
antibody and MFU50-C10-HRP as detection antibody-
conjugate. Mtb culture filtrate (Mtb cultivated in 7H9 +
ADC +Tween for 3 months at 37°C) was analysed by α-85
B sandwich titration ELISA (Figure 6A, red curve). This
resulted in weak binding barely distinguishable from the
medium control (Figure 6A, pink curve). Mtb culturelture filtrates determined by indirect ELISA. 100 ng/100 μL of the
d with a scFv-Fc concentration of 2.5 μg/mL. Detection of bound
Figure 5 A-85 B sandwich antigen titration ELISA. 100 ng of capture scFv-Fc were directly coated to the wells. After blocking different
dilutions of antigen were applied and incubated. Detection of bound antigen with: A) MFU50-A10-scFv-Fc-HRP at ~0.05 μg/mL and development
with TMB. Negative control (BSA) A450 = 0.02, B) MFU50-C10-scFv-Fc-HRP at ~0.05 μg/mL and development with TMB. Negative control (BSA)
A450 = 0.05, C) MFU50-D4-scFv-Fc-HRP at ~0.05 μg/mL and development with TMB. Negative control (BSA) A450 = 0.02.
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(Figure 6A, black curve). In this assay there was no in-
crease of the signal by increasing of sample volume. Add-
itionally, Mtb cell extract was analysed by α-85 B sandwich
titration ELISA (Figure 6B, red curve). This showed no
binding distinguishable from the negative control except
for the highest concentration (Figure 6B, grey curve). How-
ever, in a direct α-85 B ELISA specific binding to Mtb cell
extract was observed (Figure 6B, black curve).
Effect of sample treatment on 85 B detection
The failed detection of 85 B in Mtb cell extract in sand-
wich ELISA compared to the successful detection in
direct ELISA was further analysed. It was hypothesizedFigure 6 Mtb culture filtrate and Mtb cell extract titration in α-85 B d
or B) different dilutions of Mtb cell extract were directly coated to the well
at ~ 0.05 μg/mL and development with TMB. Sandwich ELISA: 100 ng of ca
blocking A) various volumes of Mtb culture filtrate or B) different dilutions
antigen with MFU50-C10-scFv-Fc-HRP at ~0.05 μg/mL and development w
cell extract all A450 = 0.05.that the sample treatment, especially autoclaving, was
the cause for differing antigen detection. Cell extracts
were prepared by autoclaving at 121°C for 20 min. The
influence of sample pretreatment by heat on 85 B detec-
tion was investigated by direct ELISA (Figure 7). When
85 B was boiled, antigen binding was reduced. Further
examination of the susceptibility of 85 B to heat was
carried out by analytical SEC. The theoretical molecular
mass of an 85 B monomer was computed with the
ExPASy prot param tool [38] to 34.6 kDa. The untreated
sample of 85 B displayed a small monomer peak at
33.8 kDa and a dominant multimer peak with a molecular
mass out of the measurement range but definitely greater
than 669 kDa (Figure 8A). In comparison the boiled 85 Birect and sandwich ELISA. A) various volumes of Mtb culture filtrate
s. After blocking antigen was detected using MFU50-C10-scFv-Fc-HRP
pture scFv-Fc MFU50-A10 were directly coated to the wells, after
of Mtb cell extract were applied and incubated. Detection of bound
ith TMB. Negative controls: BSA, M. smegmatis cell extract, M. vaccae
Figure 7 Detection of boiled 85 B by α-85 B direct ELISA.
100 ng of antigens in PBS (boiled for 20 min at 100°C or directly
taken from storage at 2 – 8°C) were coated to the wells. After
blocking bound antigen was detected using MFU50-A10/-C10/-D4-
scFv-Fc-HRP at ~0.05 μg/mL and development with TMB. Negative
control BSA A450 = 0.02.
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(34.6 kDa), multiple peaks with lower molecular mass and
a few non-dominant multimer peaks (Figure 8B). Interest-
ingly, aggregation was greater in the untreated sample
than in the boiled sample. It was concluded that theFigure 8 Analytical SEC of antigen 85 B (batch 09-2/1). A) Sample stor
were applied to Superdex 200 10/300 GL column. Running buffer was PBS
23 min, 4. 150 kDa 24 min, 5. 66 kDa 26 min, 6. 29 kDa 31 min, 7. 12.4 kDaaggregation improved sandwich detection, and if multi-
mers were detected by sandwich ELISA, the use of the
same antibody for capturing and detection should be pos-
sible. Experimental study by sandwich ELISA (Figure 9)
verified this assumption. In the untreated as well as in the
boiled sample, sandwich detection with only one antibody
was possible (Figure 9, arrows).
Development of a lateral flow immuno assay
To develop a Lateral Flow Immuno Assay (LFIA) all α-
85 B scFv-Fc were conjugated to 40 nm colloidal gold.
Sandwich 85 B detection was performed with all avail-
able antibodies for capturing and all antibody-gold con-
jugates for detection. The most suitable combination,
MFU50-A10 as capture antibody and MFU50-D4-gold
as detection antibody, was further analysed. A procedure
that allowed sensitive antigen detection and low back-
ground combined with good feasibility was developed
(data not shown). The 85 B detection limit was deter-
mined by sandwich LFIA to ≤ 5 ng/mL (Figure 10). Mtb
cell extract or culture filtrate (concentrated and uncon-
centrated) were analysed by α-85 B sandwich LFIA. Un-
fortunately, 85 B was not detectable in any sample in
this assay.ed at 2 – 8°C, B) sample boiled for 20 min at 100°C. 500 μL of sample
pH 7.4. Standards: 1. 669 kDa 17 min, 2. 443 kDa 20 min, 3. 200 kDa
34 min, 8. 6.5 kDa 37 min.
Figure 9 Detection of 85 B multimers in α-85 B sandwich ELISA. 100 ng of capture scFv-Fc were coated to the wells. After blocking
100 ng of 85 B in PBS (untreated or boiled for 20 min at 100°C) were applied to the wells and incubated. Bound antigen was detected using
A) MFU50-A10 B) MFU50-C10 and C) MFU50-D4-scFv-Fc-HRP at ~0.05 μg/mL and development with TMB. Negative control BSA A450 = 0.05.
Multimer-detection is indicated by arrows.
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of 85B
Sandwich detection of antigen 85 B in Mtb culture fil-
trates and cell extracts was complex in previously de-
scribed sandwich ELISA and LFIA. As an alternative a
direct α-85 B immunoblot assay was developed to avoid
the challenge of sample pretreatment in sandwich detec-
tion. Furthermore, Mtb was cultured in Sauton’s min-
imal medium and culture filtrates were concentrated to
increase the antigen quantity. Weekly samples were taken,
concentrated 20 to 30 fold and analysed by reducing gel
analysis via Tape Station and α-85 B immunoblot. No 85 BFigure 10 A-85 B sandwich LFIA, determination of detection limit. 100
pH 8.8 containing 8% BSA were applied on sample pad, read out after 20 mwas detected in 7 and 16 days old cultures by either means
(data not shown). After 22 days a protein band at ~30 kDa
(according to Tape Station analysis, Figure 11B) was rec-
ognized by MFU50-A10 in immunoblot (Figure 11A).
Additionally, 85 B expression was found in 61 and 70 days
old cultures (data not shown). The Tape Station and α-85
B immunoblot results for 22 and 76 days old cultures are
given in Figure 11.
Discussion
Tuberculosis is the leading cause of death due to bacter-
ial infections worldwide [1]. State of the art TB detectionμL sample (7H9 medium spiked with 85 B) + 50 μL 2.2 mM borax
in.
Figure 11 Detection of 85B by immunoblot. A) A-85 B immunoblot and B) Tape Station analysis of concentrated Mtb culture filtrates (22 d
and 76 d at 37°C). A) 100 ng of recombinant 85 B, 25 μL of concentrated Mtb culture filtrates (after 22 or 76 days at 37°C in Sauton’s medium)
and 8 μL of marker (M) were separated on reducing 12% SDS-PAGE and electro blotted to a PVDF membrane. After blocking, blots were
incubated with scFv-Fc-HRP, development with TMB. B) Samples were directly analysed by reducing gel analysis via Tape Station.
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ture [39]. In developing countries, a rapid, cheap and
easy to use POC TB test is needed [9]. The WHO does
not recommend the detection of antibodies against Mtb
[10]. The only available assay for direct Mtb antigen de-
tection is that against mycobacterial Lipoarabinomannan
(LAM). However this test displays poor sensitivity apart
from in patients with advanced HIV/AIDS [40].
In this work, we isolated and characterized specific
antibodies against Mtb antigen 85 B. These antibodies
were proved suitable for 85 B sandwich detection in
ELISA and LFIA. In addition, an Mtb immunoblot assay
was developed.
Five unique antibodies were selected from the human
naïve libraries HAL7/8 [33]. The examined antibodies
displayed homogeneity in the subfamily of the variable
gene segment of the heavy chain (all VH3). This corre-
lates with the overrepresentation of VH1 and VH3 in the
HAL7/8 libraries [41] and in vivo [42]. Four antibodies
have a lambda light chain, one a kappa light chain. Ac-
cording to Løset et al. [43] lambda scFv are expressed in
higher yields in E. coli compared to kappa scFv, which
may lead to an advantage in phage display [33,41]. The
antibody MFU50-C10 has a germline combination of VH3
and Vκ1, which is common in vivo and in naïve libraries
[33,42,44]. The lambda germline sequences present in the
other antibodies are from the subfamilies 2, 3, 7 and 8.
Subfamilies Vλ1,2 and 3 are dominant in vivo, whereupon
Vλ7 and 8 are rare in vivo [42,44]. In the HAL7 library
Vλ7 and 8 are more frequent than in vivo [33].
Ferrara et al. [22] selected 48 antibodies directed against
the Mtb 85 complex in a combination of yeast and phage
display. None of these antibodies were specific for anindividual 85 antigen but, cross reacted with all other 85
complex proteins. Landowski et al. [45] isolated an α-85 B
chicken IgY which cross reacted with 85 complex proteins.
Drowart et al. [21] generated seven monoclonal α-85 com-
plex antibodies, which all cross reacted with other myco-
bacterial species however none were specific for antigen
85 B. This study shows the isolation of the first human
recombinant antibodies (MFU50-C10, MFU50-D7 and
MFU50-E2) specific for antigen 85 B. Furthermore four α-
85 A antibodies (MFU12-D8, MFU53-A3, MFU53-F3 and
MFU53-G2) and three α-85 D antibodies (MFU51-A6,
MFU51-B10 and MFU53-C2) were generated (unpub-
lished data). MFU12 -D8 was found to be specific for
antigen 85 A and MFU51-B10 was specific for 85 D.
These antibodies allow for the discrimination between
individual components of the 85 complex. Antibody
phage display using human naive antibody gene libraries
allows for the selection against non-immunogenic pro-
teins and epitopes. We propose these epitopes, which
would allow discrimination between the different 85
proteins, are not immunogenic. We propose this be-
cause of the fact that no antibodies, specific for one
component of the 85 complex, were isolated by hybrid-
oma technology [21,23].
Easy applicability to in vitro assays was showed in this
study by conjugation to colloidal gold or HRP. Due to
the recombinant nature of the explored antibodies, they
can easily be altered to different formats, fused to differ-
ent Fc-parts [34] or fused to markers such as green
fluorescent protein (GFP, [46]) for in vivo experiments.
Thereby the role of particular 85 proteins in Mtb cell wall
biosynthesis and evasion of the host’s immune response
may be investigated.
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tinuous sequences of the antigen, and the corresponding
epitopes were determined by screening overlapping pep-
tides immobilized on a cellulose membrane. MFU50-D4
recognized the epitope “AFSRPGLPVEYL” and MFU50-
D7 recognized the epitope “AFSRPGLPV”. This epitope
region seems to be a potent T cell antigen since syn-
thetic peptides including this sequence were found to in-
duce cytokine release or immune cell proliferation in
peripheral blood of individuals with varying TB status
[47-50]. However only weak human B cell responses
against these peptides were reported [49,51]. Interest-
ingly, no antibodies against this epitope were generated
by immunization. In this work, human antibodies were
successfully generated by screening phage display librar-
ies, fortifying the advantage of phage display technology
over conventional immunization methods. Protein se-
quence comparison of the 85 complex proteins revealed
the presence of the epitope in antigen 85 A and 85 C,
suggesting cross reactivity. In ELISA and immunoblot
analysis MFU50-D7 showed no 85 A binding, however
MFU50-D4 showed slight cross reactivity with 85 A.
During this study 85 C was not available for examination.
Furthermore, a protein blast search (BLASTP, [52]) dis-
closed the existence of the entire epitope in several dif-
ferent mycobacterial strains (i.e. M. bovis, M. ulcerans,
M. marinum, M. smegmatis, M. vaccae, etc.), suggesting
cross reactivity.
The α-85 B antibodies MFU50-A10 and MFU50-E2
recognize the epitopes “SSDPAWERNDPT” and “SSDPA-
WERN” respectively. Landowski et al. [45] generated an
oligoclonal chicken IgY antibody against the peptide
“SSDPAWERNDPT” (epitope ID 60953, IEDB) and dem-
onstrated 55% sensitivity and 85% specificity for detection
of circulating 85 B in human blood by an immunoblot
approach. Shen et al. [51] reported the synthetic peptide
“GPSSDPAWERNDPTQ QIPKL” (epitope ID 21797,
IEDB) was recognized by sera (IgG) of TB + individuals.
Similar peptides containing the epitope “SSDPAWE
RNDPT” were found to induce cytokine release or T
cell proliferation in various assays with samples of
TB + individuals [49,50,53-55]. The entire amino acid
sequence “SSDPAWERNDPT” is present only in 85 B
of M. tuberculosis and M. bovis BCG. Homologous
sequences in Mtb 85 A or 85 C and in 85 complex
proteins from other mycobacterial species (identified
by BLASTP) differed primarily by substitution of one
amino acid. Cross reactivity of MFU50-A10 with Mtb
85 A and M. bovis BCG cell extract and culture filtrate was
detected by indirect ELISA and immunoblot. Landowski
et al. [45] found a “SSDPAWERNDPT” specific chicken
IgY antibody to be cross reactive with Mtb 85 A and 85 C
as well as 85 complex proteins of M. avium. The reaction
of MFU50-A10 with 85 A, B and D indicates a possiblesmaller epitope than determined by epitope mapping. The
amino acid sequence “DPA” is present in antigen 85 A, B
and C, but the adjacent amino acids differ. In 85 B the
“DPA” is flanked by serine on the N-terminal site and
tryptophan on the C-terminal site (“SDPAWE”). In 85 A
glutamic acid is N-terminal and tryptophan C-terminal
(“EDPAWQ”). In 85 D serine is N-terminal and alanine
C-terminal (“SDPAAM”). It seems possible that the
epitope of MFU50-A10 is “SDPAW” or “DPAWE”, which
would mean that two amino acids are different in 85 A or
85 D respectively. This would explain the weaker recogni-
tion of 85 A and 85 D. Furthermore, the comparison of
the 3D structures of antigen 85 A and 85 B (Figure 12) re-
vealed that the glutamic acid in 85 B forms a pin structure
in front of the “DPAW” region. This formation is missing
in 85 A, instead of glutamic acid there is glutamine. Glu-
tamic acid can mediate strong electrostatic attractions and
hydrogen bridges through the loaded carboxylgroup,
whereupon glutamine is uncharged and can only mediate
hydrogen bridges through the amino- and the ketogroup
[56]. Thus, it is reasoned that the glutamic acid pin
structure is needed structurally for correct docking, and
physico-chemically for full strength binding to the
antigen.
MFU50-C10 recognizes the epitope “SPAVYL”, which
is close to the suggested active site of antigen 85 B [36],
offering a possible inhibitory effect by steric hindrance
[57]. Synthetic peptides including this epitope were
found to induce cytokine release and T cell proliferation
in peripheral blood mononuclear cells of TB + humans
[49,50,54,58] and antibodies against these peptides were
detected in sera of TB + individuals [51,59]. Sequence
comparison of Mtb 85 complex proteins revealed no
homology in this area. According to BLASTP equivalent
sequences are present in several other mycobacterial
species (i.e. M. bovis, M. marinum, M. leprae, M. vaccae,
M. ulcerans, M. avium, etc.). No cross reactivity with 85
A and 85 D was detected by indirect ELISA and immu-
noblot, suggesting specificity for antigen 85 B. Surpris-
ingly, no cross reactions with M. bovis BCG cell extract
and culture filtrate were detected in an indirect ELISA.
Sandwich ELISA detection of recombinant 85 B with
the α-85 B Yumabs was successful in all performed assays.
The most suitable combination was capturing with
MFU50-A10 and detection with MFU50-C10-HRP, reach-
ing a detection limit of ~10 ng/mL. Sandwich LFIA detec-
tion of recombinant 85 B was successful capturing with
MFU50-A10 and detecting with MFU50-D4-gold. A de-
tection limit of 5 ng/strip (0.03 ng/mL) was evaluated.
There are no published reports on single antigen 85 B
sandwich detection, only whole 85 complex sandwich as-
says [20,22-24,39,45,60].
Sandwich detection of recombinant 85 B was enhanced
by multimeric antigen conformation, and reduced by
Figure 12 3 D structures of antigens A) 85 A and B) 85 B around the amino acid sequence “DPAW”. A) Pdb1sfr (Resolution 2.7 Å, [75])
and B) Pdb1f0n (Resolution 1.9 Å, [36]) were modified with 3D molecule viewer (Invitrogen). Respectively only protein chain A is shown, atoms
are displayed as space filling balls, “DPAW” is marked in blue, glutamic acid in 85 B is encircled in comparison to glutamine in 85 A.
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antigen (~5 nm diameter, [36]) may be responsible for this
finding. Considering the length of a human scFv of ~
4.5 nm [37] and the Fc-mediated homodimerisation of
scFv-Fc fusions [34,61], sterical inhibition by the capture
antibody is possible. The commercially available immuno-
chromatographic assays for MPT64 antigen detection in
Mtb cultures are sandwich assays with monoclonal anti-
bodies [62]. The Capilia TB Test Kit [63] uses only one
monoclonal antibody for a sandwich assay, indicating
multimer detection. Recombinant antigen MPT64 showed
multimerization by disulphide bonds in two unrelated
studies [64,65] and no difference in immunogenicity com-
pared to native antigen [64,66]. These findings imply mul-
timerization of native MPT64 and that these aggregates
are detected in sandwich assays. Detection of 85 B in
culture filtrates was only possible with MFU50-A10 in
direct ELISA and immunoblot. MFU50-A10 was cross
reactive with 85 A and 85 D in ELISA and immunoblot-
ting. It has been reported to cross react with 85 C by
Landowski et al. [45].Table 3 Cloned genes of M. tuberculosis antigen 85
complex and properties of the recombinant gene
products
Gene Vector Gene product
Antigen Signal sequence His-tag
fbpA (Rv3804c) pET26b 85 A No N-terminal
fbpB (Rv1886c) pET22b 85 B Yes no
fbpD (Rv3803c) pET28c 85 D Yes N-terminalConclusions
This work identifies the first recombinant human scFv
antibodies specific for antigen 85 B selected by phage dis-
play from naïve antibody gene libraries (HAL7/8). These
antibodies allow the discrimination between 85 complex
proteins, and showed suitability for the establishment of
different assays for Mtb 85 B detection. Antigen conform-
ation influenced by sample treatment was shown to be im-
portant. The presented antibodies are candidates for the
future development of a POC TB diagnostic kit. However,
for this purpose an affinity maturation of the antibodies
would be necessary to improve the sensitivity.Material and methods
All chemicals used were p.a. purity grade and purchased
from Sigma Aldrich, Merck or Carl Roth (all located in
Germany) or as indicated otherwise.Antigen purification
Genes fbpA, B, D coding for proteins of antigen 85 com-
plex of M. tuberculosis were amplified by PCR and inserted
into pET expression vectors (Novagen, Germany) by site
directed cloning (Table 3).
Exchanges L78Q and S196T within the derived amino
acid sequence of 85B, and exchange F54L within 85C
were detected by DNA sequencing.
Recombinant 85A was produced in E. coli strain BL21
(DE3) [pLysS] (Novagen, Germany) by growth in LB [67]
containing 400 μg/mL ampicillin and 34 μg/mL chloram-
phenicol. Expression was induced by addition of 1 mM
IPTG at mid-log-phase. Cells were harvested 4 hours after
induction. 85 B and 85 C were produced using BL21(DE3)
(Novagen, Germany) as host strains grown in LB contain-
ing 50 μg/mL kanamycin. After induction with 1 mM
IPTG at mid-log-phase, cells were incubated overnight
and then harvested.
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Cells were suspended in 10 mM tris/HCl, pH 8.0 contain-
ing 1% Triton X-100 and 10 mM EDTA (10 mL per g wet
weight). After cell disruption by sonification and centrifu-
gation the pellet was washed once using the same buffer.
The pellet was denatured in 20 mM tris/HCl, pH 8.0, 1%
Triton X-100 buffer containing 8 M urea and 2 mM DTT.
After centrifugation the supernatant containing the de-
natured 85 B antigen was bound on a Q-Sepharose High
Performance column (GE Healthcare) and eluted by a
linear gradient from 0 to 500 mM NaCl. Fractions con-
taining 85 B antigen were pooled and underwent a buf-
fer exchange step on a Sephadex G25 fine column (GE
Healthcare) into the buffer described above without Tri-
ton X-100. The protein containing pool was subjected to
another chromatography step on a Q-Sepharose High Per-
formance column (GE Healthcare). Again protein elution
was performed by a linear gradient from 0 – 500 mM
NaCl. Pure antigen 85 B containing fractions were pooled
and underwent a final refolding and buffer exchange step
on a Sephadex G25 fine column (GE Healthcare) into
10 mM NH4HCO3, 100 μM DTT, pH 7,9.
The final protein preparation is a mixture of protein
containing the signal sequence and lacking the signal se-
quence. Approximately 90% of the protein shows the
signal sequence and approximately 10% lacks the signal
sequence.
85 A purification
Cells were suspended in 20 mM tris/HCl, 100 mM NaCl,
pH 8.0 (10 mL per gram wet weight). After cell disruption
by sonification and centrifugation, imidazole was added to
the supernatant to a final concentration of 5 mM. This so-
lution was applied on a Ni-NTA Superflow column (GE
Healthcare) and eluted by a linear gradient from 0 to
500 mM imidazole. Fractions containing 85 A antigen
were pooled and underwent a buffer exchange step on a
Sephadex G25 fine column (GE Healthcare) into 20 mM
tris/HCl, pH 8.0. Chromatography using a Q-Sepharose
High Performance column (GE Healthcare) was per-
formed on the pooled protein sample. Protein elution was
performed using a linear gradient from 0 – 500 mM NaCl.
Pure antigen 85 A containing fractions were pooled and
underwent a final buffer exchange step on a Sephadex
G25 fine column (GE Healthcare) into 10 mM NH4HCO3,
pH 7.9.
85 D purification
Cells were suspended in 20 mM tris/HCl, 100 mM NaCl,
pH 8.0 containing 1% Triton X-100 (10 mL per gram
wet weight). After cell disruption by sonification and
centrifugation the pellet was washed once using 20 mM
tris/HCl, 100 mM NaCl, pH 8.0 containing 1% Triton X-
100. Afterwards the pellet was denatured in 20 mM tris/HCl, 100 mM NaCl, pH 8.0 containing 8 M urea. After
centrifugation the supernatant containing the denatured
85 D antigen underwent a refolding step on a Sephadex
G25 fine column (GE Healthcare) into 20 mM tris/HCl,
100 mM NaCl, pH 8.0. The protein peak of this refolding
step was collected and then bound on a Q-Sepharose High
Performance column (GE Healthcare). Protein elution was
performed by a linear gradient from 0 to 300 mM NaCl.
Fractions containing pure 85 D antigen were pooled and
underwent a buffer exchange step on a Sephadex G25 fine
column (GE Healthcare) into 10 mM NH4HCO3, pH 7,9.
For final endotoxin removal the protein solution was
passed four times over a 1 mL Profos endotrap red col-
umn (Hyglos GmbH).
Selection of human antibodies using phage display
ScFv were isolated in vitro from the human naïve phage
libraries HAL7/8 by panning on decreasing amounts (10,
3 and 1 μg) of immobilized recombinant antigen 85 B ac-
cording to [68].
Production of soluble scFv antibodies for screening ELISA
The identification of monoclonal binders was performed
as described in [69] with the following modifications:
96-well polypropylene (PP) micro titer plates (Greiner,
Germany) containing 150 μL 2xYT-G/A (2xYT [67] sup-
plemented with 100 mM glucose and 100 μg/mL ampi-
cillin) were inoculated with colonies from the titration
plate of the third panning round. Micro titer plates
(MTP) were incubated overnight at 37°C and 850 rpm in
a MTP shaker (PST-60HL-4, Lab4you, Austria). A volume
of 180 μL 2xYT-G/A per well in PP-MTP was inoculated
with 10 μL of the overnight culture and grown at 37°C
and 850 rpm for two hours. Bacteria were harvested by
centrifugation for 10 min at 3,220 × g and 180 μL super-
natant were removed. The pellets were resuspended in
180 μL 2xYT supplemented with 50 mM sucrose and
100 μg/mL ampicillin + 50 μM IPTG and incubated at
30°C and 850 rpm overnight. Bacteria were pelleted by
centrifugation for 15 min at 3,220 × g and 4°C. The
scFv-containing supernatant was transferred to a new
PP-MTP and stored at 4°C prior to analysis.
Screening ELISA
96 wells of Microlon MTP (Greiner, Germany) were
coated with 100 ng of recombinant 85 B in 100 μL PBS
buffer pH 7.4 or BSA in 100 μL PBS buffer pH 7.4 (Carl
Roth, Germany) as a negative control [67] overnight at
4°C. After coating, the wells were blocked with 300 μL
PBST-B (PBS supplemented with 0.1% (w/v) Tween-20
and 1% (w/v) BSA) for 2 h at RT. This was followed by
three washing steps with PBST0.05 (PBS supplemented
with 0.05% (w/v) Tween-20). For identification of binders,
supernatants containing monoclonal scFv were incubated
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three PBST washing cycles. Bound scFv were detected
using mouse α-c-Myc-tag 9E10 (culture supernatant,
100 μL, 1:1,000 in PBST-B; 1.5 h at RT) followed by goat
α-mouse IgG (Fc)-HRP (A0168, Sigma-Aldrich, Germany)
(100 μL, 1:30,000 in PBST-B; 45 min at RT). After three
washing steps with PBST0.05 the reactions were visual-
ized with 100 μL 3,3’,5,5’-tetramethylbenzidine (TMB,
Seramun, Germany) as a substrate. The staining reac-
tion was terminated by addition of 100 μL 0.2 M H2SO4.
Absorbance at 450 nm (620 nm reference) was mea-
sured using MRX ELISA reader (Dynatec, Germany).Antibody titration ELISA
For each antibody, 24 wells of Greiner Microlon MTP
were coated with 100 ng antigen in PBS at 4°C over-
night. BSA was coated as a negative control. After coat-
ing, the wells were blocked with PBST-B for 2 h at RT,
followed by three washing steps with PBST0.05. Twelve
dilutions of antibody (differing, depending on the anti-
body) in PBST-B were applied in duplicates on the antigen
and BSA controls and incubated for 1.5 h at RT. Bound
scFv-Fc were detected using goat α-human IgG (Fc)-HRP
(A0170, Sigma-Aldrich, Germany) (100 μL, 1:130,000 in
PBST-B; 45 min at RT). The assay was further processed
as described above.Antigen titration ELISA
Antigen in PBS at twelve dilutions (1 μg/mL to 0.5 ng/
mL) were coated in duplicates to wells of Greiner Micro-
lon MTP at 4°C overnight. BSA coated wells were used
as a negative control. After coating, the wells were blocked
with PBST-B for 2 h at RT, followed by three washing
steps with PBST. Antigen detection was carried out with a
concentration of antibody at half maximal saturation (de-
termined by antibody titration ELISA) in PBST-B for 1.5 h
at RT followed by three PBST washing cycles. Bound
scFv-Fc were detected using goat α-human IgG (Fc)-HRP
(100 μL, 1:130,000 in PBST-B; 45 min at RT). The assay
was further processed as described above.Direct ELISA
Analyte (antigen or antibody) was coated to the surface
of Greiner Microlon 96 Well MTP at various concentra-
tions in PBS buffer overnight at 4°C. Detection of anti-
gen was carried out with an scFv-Fc antibody conjugated
to HRP (by EZ-Link Plus Activated Peroxidase Kit, Pierce,
Germany, according to the manufacturer’s instructions)
diluted in PBST-B for 1 h at RT. Detection of antibody
was carried out with Goat a-human IgG (Fc)-HRP diluted
(100 μL, 1:130,000 in PBST-B) 45 min at RT. The assay
was further processed as described above.Sandwich antigen titration
100 ng of capture antibodies were coated to the surface
of 96 wells of Greiner Microlon MTP in PBS buffer
overnight at 4°C. After coating, the wells were blocked
with PBST-B for 2 h at RT, followed by three washing
steps with PBST. Twelve dilutions of antigen in PBST-B
were applied in duplicates onto the antibody coated
wells and incubated for 1.5 h at RT, followed by three
washing steps with PBST. Detection of bound antigen
was performed with HRP conjugated scFv-Fc (exact dilu-
tions described in results) in PBST-B for 1.5 h at RT,
followed by three washing steps with PBST. The assay
was further processed as described above.
Epitope Mapping
The protein sequence of 85 B (Rv1886c, UniProt ID
P0C5B9, sequence source: http://genolist.pasteur.fr/
TubercuList/) was divided into overlapping peptide
fragments, each consisting of 15 amino acids, with an
offset of three amino acids. This array of peptides was
synthesized by the SPOT technique [70,71] on an amino-
pegylated cellulose membrane (AIMS Scientific Products
GmbH, Wolfenbüttel, Germany) as described previously
[72]. Peptides are N-terminally acetylated and remain co-
valently attached to the membrane via their carboxy-
terminus. The membrane bound peptide array was probed
with the α-85 B antibodies for binding according to estab-
lished procedures [30,72].
Immunoblot
Proteins were separated on 12% SDS-PAGE [73,74] and
semi-dry blotted onto polyvinylidene fluoride (PVDF)
membranes (Carl Roth, Germany) according to the man-
ufacturer’s instructions. Blocking was performed with
MPBST (PBST0.1 supplemented with 2% (w/v) dry milk)
for minimum 30 min at RT. Subsequent incubation with
protein-specific antibody was carried out in MPBST for
a minimum of 60 min at RT. Three washing steps with
PBST0.1 for 5 min were performed. The PVDF mem-
brane was incubated with a secondary antibody coupled
to HRP in MPBST for at least 45 min at RT. The blot
was washed another three times with PBST0.1 and then
developed with TMB peroxidase membrane substrate
(Seramun, Germany) until an adequate signal was ob-
tained. Development was stopped by three short washing
steps with deionized water.
LFIA assembly + execution
5 – 40 μL cm−1 of colloidal gold-antibody conjugates were
dispensed onto 8 mm glass fibre pads (Millipore, Germany)
using the xyz-dispenser (Biodot, USA) and dried at 37°C.
1 μL cm−1 of different concentrations of capture antibody
solution (sandwich assay) or antigen (direct assay) in PBS
were dispensed in a line onto Unisart CN 95 nitrocellulose
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already assembled onto 300 mm backing cards (Jieyi
Biotechnology, China), and dried at 37°C. The glass
fibre conjugate pads were laminated onto the backing
cards, overlapping the nitrocellulose membrane at the
connection point for ~ 0.5 – 1 mm. Then cellulose fibre
pads (Millipore, Germany) were laminated onto the
backing cards as sample and wicking pad, overlapping
the nitrocellulose membrane at the connection point
for ~ 0.5 – 1 mm. The assembled cards were cut into
strips of 0.4 cm width with the CM4000 guillotine-cutter
(Biodot) and the test strips were placed into Lateral Flow
Strip Test (LFST) cassettes (Jieyi Biotechnology, China).
Several experiments were carried out to determine a
procedure that would allow sensitive antigen detection
and a low background combined with good feasibility
(data not shown). The best option for a manageable
LFIA was to add a diluent to the sample before applying
it to the sample well. Therefore 1/3 sample volume
(50 μL) of conjugation buffer (2 mM borax pH 8.8)
enriched with 8% (w/v) BSA were mixed with 100 μL
sample and applied to the LFIA. After 15 – 20 min re-
sults were optically evaluated.
Yumab production + purification
All scFv isolated from antibody-phage display were sub-
cloned into pCSE2.5-hIgG1-Fc-XP and produced as scFv-
Fc (yumab) in HEK293-6E cells (National Research Council
(NRC), Biotechnological Research Institute (BRI), Montreal,
Canada). HEK293-6E cells were cultured in chemical
defined F17 medium (Invitrogen, Life Technologies,
Darmstadt, Germany) supplemented with 1 g/L pluronic
F68 (Applichem, Darmstadt, Germany), 4 mM L-glutam-
ine (PAA) and 25 mg/L G418 (PAA) as previously de-
scribed [34]. DNA was transiently transfected into 25 mL
HEK293-6E cells in 125 mL Erlenmeyer shake flasks.
After 48 hours of cultivation at 110 rounds per minute
(rpm) in a Minitron orbital shaker (Infors, Bottmingen,
Switzerland) at 37°C and 5% CO2 atmosphere, one vol-
ume culture medium and a final concentration of 0.5%
(w/v) of tryptone N1 (TN1, Organotechnie S.A.S., La
Courneuve, France) were added. ScFv-Fc were purified via
UNOsphere SUPrA column (Biorad, Munich, Germany)
using a Profinia automate (Biorad, Hercules, California,
USA), according to the manufacturer’s instructions.
Analytical SEC
For analytical size exclusion chromatography (SEC) a
Knauer PLATINblue HPLC Plus system (Knauer, Germany)
with a Superdex 200 10/300 GL column (GE Healthcare,
USA) was used according to the manufacturer’s instruc-
tions. The column was equilibrated with the Gel Filtration
HMW/LMW Calibration Kits (GE Healthcare, USA) ac-
cording to the manufacturer’s instructions.Tape Station
Protein solutions were analysed with the Screen Tape
P200 Protein Standard Kit (Agilent, USA) under redu-
cing conditions on a 2200 Tape Station system (Agilent,
USA) according to the manufacturer’s instructions. The
“P200 molecular weight standard” (Agilent) was used as
a molecular marker.
Additional file
Additional file 1: Figure S1. Screening ELISA for 85 B binding scFv in
HAL7/8. Culture supernatants containing soluble scFv of 92 single clones
(3. panning round) were screened for their ability to bind antigen (85 B)
and BSA (negative control). On positions H9 and H12 an anti-lysozyme
antibody was used on lysozyme as control for scFv production and ELISA
detection system. Detection of bound scFv with mouse α-c-Myc-tag 9E10
IgG followed by goat α-mouse IgG(Fc)-HRP, development with TMB.
Competing interests
The authors have no competing financial or non-financial interests. This study
was financially supported by the German Federal Ministry of Commerce, Grant
No. KF 2584301. All aspects of cooperation and the generated results by the
partner organisations have been mentioned in the cooperation agreement of
the grant as required by the German Federal Ministry of Commerce. We did
not receive any other financial or personal contribution by any other third party.
Currently, there are no plans to file a patent. Following the rules of the German
Federal Ministry of Commerce, LIONEX reserves its rights to develop any
product based on the results or materials of this manuscript but agrees to
provide the materials to research organisations only, exclusively for
research use.
Authors’ contributions
MF performed most of the experiments, participated in the design of the
study, analysed data and drafted the manuscript. SK, SH, WP, RS, WO and RF
performed some of the experiments, analysed data and provided material.
SD participated in the design of the study and analysed data. MS and MH
conceived the project and wrote the grant application, participated in the
design of the study, analysed data and drafted the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
We kindly acknowledge the technical support of Susanne Daenicke and
Franziska Resch. Further, we acknowledge the financial support of ZIM BMBF
(contract No. KF 2584301). We also thank Elizabeth O’Brien for the careful
correction of this manuscript.
Author details
1Technische Universität Braunschweig, Institut für Biochemie und
Biotechnologie, Spielmannstr.7, 38106 Braunschweig, Germany. 2Lionex
GmbH, Salzdahlumer Str. 196, 38126 Braunschweig, Germany. 3Helmholtz
Zentrum für Infektionsforschung, Abteilung Chemische Biologie, Inhoffenstr. 7,
38124 Braunschweig, Germany. 4Leibniz-Institut für Molekulare Pharmakologie,
Robert-Roessle-Str. 10, 13125 Berlin, Germany.
Received: 22 April 2014 Accepted: 1 July 2014
Published: 17 July 2014
References
1. WHO: Global Tuberculosis Report 2012. Geneva, Switzerland: 2012.
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC: Consensus statement.
Global burden of tuberculosis: estimated incidence, prevalence, and
mortality by country. WHO Global Surveillance and Monitoring Project.
JAMA 1999, 282:677–686.
3. Kumar V, Robbins SL: Robbins basic pathology. 8th edition. Philadelphia, PA:
Saunders/Elsevier; 2007.
4. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, Owens MR,
Rodgers R, Banada P, Safi H, Blakemore R, Lan NTN, Jones-Lopez EC, Levi M,
Fuchs et al. BMC Biotechnology 2014, 14:68 Page 15 of 16
http://www.biomedcentral.com/1472-6750/14/68Burday M, Ayakaka I, Mugerwa RD, McMillan B, Winn-Deen E, Christel L,
Dailey P, Perkins MD, Persing DH, Alland D: Rapid Detection of
Mycobacterium tuberculosis and Rifampin Resistance by Use of
On-Demand, Near-Patient Technology. J Clin Microbiol 2010, 48:229–237.
5. Rai DR, Kshetry NT, Bhargava D, Pokhrel BM: Comparison of Ziehl-Neelsen
staining microscopy and immunochromatographic tuberculosis test for
diagnosis of pulmonary tuberculosis. J Inst Med 2006, 28:15–18.
6. van Deun A, Portaels F: Limitations and requirements for quality control
of sputum smear microscopy for acid-fast bacilli. Int J Tuberc Lung Dis
1998, 2:756–765.
7. Steingart KR, Ng V, Henry M, Hopewell PC, Ramsay A, Cunningham J,
Urbanczik R, Perkins MD, Aziz MA, Pai M: Sputum processing methods to
improve the sensitivity of smear microscopy for tuberculosis: a
systematic review. Lancet Infect Dis 2006, 6:664–674.
8. Perkins MD, Cunningham J: Facing the crisis: improving the diagnosis of
tuberculosis in the HIV era. J Infect Dis 2007, 196(Suppl 1):S15–S27.
9. Dheda K, Ruhwald M, Theron G, Peter J, Yam WC: Point-of-care diagnosis
of tuberculosis: Past, present and future. Respirology 2013, 18:217–232.
10. WHO: An International Roadmap for Tuberculosis Research. Geneva,
Switzerland: WHO; 2011.
11. Flores LL, Steingart KR, Dendukuri N, Schiller I, Minion J, Pai M, Ramsay A,
Henry M, Laal S: Systematic Review and Meta-Analysis of Antigen
Detection Tests for the Diagnosis of Tuberculosis. Clin Vaccine Immunol
2011, 18:1616–1627.
12. Wiker HG, Harboe M: The Antigen 85 Complex: a Major Secretion Product
of Mycobacterium tuberculosis. Microbiol Rev 1992, 56:648–661.
13. Sonnenberg MG, Belisle JT: Definition of Mycobacterium tuberculosis
culture filtrate proteins by two-dimensional polyacrylamide gel
electrophoresis, N-terminal amino acid sequencing, and electrospray
mass spectrometry. Infect Immun 1997, 65:4515–4524.
14. Wiker HG, Sletten K, Nagai S, Harboe M: Evidence for three separate genes
encoding the proteins of the mycobacterial antigen 85 complex.
Infect Immun 1990, 58:272–274.
15. Kremer L, Maughan W, Wilson R, Dover L, Besra GS: The M. tuberculosis
antigen 85 complex and mycolyltransferase activity. Lett Appl Microbiol
2002, 34:233–237.
16. Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, Besra GS: Role of the
major antigen of Mycobacterium tuberculosis in cell wall biogenesis.
Science 1997, 276:1420–1422.
17. Armitige LY, Jagannath C, Wanger AR, Norris SJ: Disruption of the genes
encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis
H37Rv: effect on growth in culture and in macrophages. Infect Immun
2000, 68:767–778.
18. Abou-Zeid C, Ratliff T, Wiker H, Harboe M: Characterization of Fibronectin-
Binding Antigens Released by Mycobacterium tuberculosis and
Mycobacterium bovis BCG. Infect Immun 1988, 56:3046–3051.
19. Abou-Zeid C, Garbe T, Lathigra R, Wiker HG, Harboe M, Rook G, Young B:
Genetic and Immunological Analysis of Mycobacterium tuberculosis
Fibronectin-Binding Proteins. Infect Immun 1991, 59:2712–2718.
20. Bentley-Hibbert SI, Quan X, Newman T, Huygen K, Godfrey HP:
Pathophysiology of antigen 85 in patients with active tuberculosis:
antigen 85 circulates as complexes with fibronectin and
immunoglobulin G. Infect Immun 1999, 67:581–588.
21. Drowart A, de Bruyn J, Huygen K, Damiani G, Godfrey HP, Stelandre M,
Yernault JC, Van Vooren JP: Isoelectrophoretic characterization of protein
antigens present in mycobacterial culture filtrates and recognized by
monoclonal antibodies directed against the Mycobacterium bovis BCG
antigen 85 complex. Scand J Immunol 1992, 36:697–702.
22. Ferrara F, Naranjo LA, Kumar S, Gaiotto T, Mukundan H, Swanson B,
Bradbury AR, Andrew RM: Using phage and yeast display to select
hundreds of monoclonal antibodies: application to antigen 85, a
tuberculosis biomarker. PLoS One 2012, 7:e49535.
23. Mukundan H, Kumar S, Price DN, Ray SM, Lee Y, Min S, Eum S, Kubicek-
Sutherland J, Resnick JM, Grace WK, Anderson AS, Hwang SH, Cho SN,
Via LE, Barry C3, Sakamuri R, Swanson BI: Rapid detection of Mycobacterium
tuberculosis biomarkers in a sandwich immunoassay format using a
waveguide-based optical biosensor. Tuberculosis (Edinb) 2012, 92:407–416.
24. Kashyap RS, Rajan AN, Ramteke SS, Agrawal VS, Kelkar SS, Purohit HJ,
Taori GM, Daginawala HF: Diagnosis of tuberculosis in an Indian
population by an indirect ELISA protocol based on detection of Antigen
85 complex: a prospective cohort study. BMC Infect Dis 2007, 7:74.25. Kashyap RS, Dobos KM, Belisle JT, Purohit HJ, Chandak NH, Taori GM,
Daginawala HF: Demonstration of components of antigen 85 complex in
cerebrospinal fluid of tuberculous meningitis patients. Clin Diagn Lab
Immunol 2005, 12:752–758.
26. Wallis RS, Perkins M, Phillips M, Joloba M, Demchuk B, Namale A, Johnson JL,
Williams D, Wolski K, Teixeira L, Dietze R, Mugerwa RD, Eisenach K, Ellner JJ:
Induction of the antigen 85 complex of Mycobacterium tuberculosis in
sputum: a determinant of outcome in pulmonary tuberculosis treatment.
J Infect Dis 1998, 178:1115–1121.
27. Kirsch MI, Hülseweh B, Nacke C, Rülker T, Schirrmann T, Marschall HJ,
Hust M, Dübel S: Development of human antibody fragments using
antibody phage display for the detection and diagnosis of Venezuelan
equine encephalitis virus (VEEV). BMC Biotechnol 2008, 8:66.
28. Meyer T, Stratmann-Selke J, Meens J, Schirrmann T, Gerlach GF, Frank R,
Dübel S, Strutzberg-Minder K, Hust M: Isolation of scFv fragments specific
to OmpD of Salmonella Typhimurium. Vet Microbiol 2011, 147:162–169.
29. Meyer T, Schirrmann T, Frenzel A, Miethe S, Stratmann-Selke J, Gerlach GF,
Strutzberg-Minder K, Dübel S, Hust M: Identification of immunogenic
proteins and generation of antibodies against Salmonella Typhimurium
using phage display. BMC Biotechnol 2012, 12:29.
30. Schütte M, Thullier P, Pelat T, Wezler X, Rosenstock P, Hinz D, Kirsch MI,
Hasenberg M, Frank R, Schirrmann T, Gunzer M, Hust M, Dübel S:
Identification of a Putative Crf Splice Variant and Generation of
Recombinant Antibodies for the Specific Detection of Aspergillus
fumigatus. PLoS One 2009, 4:e6625.
31. Chan C, Zhao B, Cazenave-Gassiot A, Pang S, Bendt A, Wenk M, Macary P,
Hanson B: Novel phage display-derived mycolic acid-specific antibodies
with potential for tuberculosis diagnosis. J Lipid Res 2013, 54:2924–2932.
32. Lillo AM, Ayriss JE, Shou Y, Graves SW, Bradbury AR: Development of
phage-based single chain Fv antibody reagents for detection of Yersinia
pestis. PLoS One 2011, 6:e27756.
33. Hust M, Meyer T, Voedisch B, Rülker T, Thie H, El-Ghezal A, Kirsch MI, Schütte M,
Helmsing S, Meier D, Schirrmann T, Dübel S: A human scFv antibody
generation pipeline for proteome research. J Biotechnol 2011, 152:159–170.
34. Jäger V, Büssow K, Wagner A, Weber S, Hust M, Frenzel A, Schirrmann T:
High level transient production of recombinant antibodies and antibody
fusion proteins in HEK293 cells. BMC Biotechnol 2013, 13:52.
35. Retter I, Althaus H, Münch R, Müller W: VBASE2, an integrative V gene
database. Nucleic Acids Res 2004, 33:D671.
36. Anderson DH, Harth G, Horwitz MA, Eisenberg D: An interfacial mechanism
and a class of inhibitors inferred from two crystal structures of the
Mycobacterium tuberculosis 30 kda major secretory protein (antigen
85B), a mycolyl transferase. J Mol Biol 2001, 307:671–681.
37. Boehm MK, Woof JM, Kerr MA, Perkins SJ: The Fab and Fc fragments of
IgA1 exhibit a different arrangement from that in IgG: a study by X-ray
and neutron solution scattering and homology modelling. J Mol Biol
1999, 286:1421–1447.
38. Artimo P, Jonnalagedda M, Arnold K, Baratin D, Csardi G, de Castro E,
Duvaud S, Flegel V, Fortier A, Gasteiger E, Grosdidier A, Hernandez C,
Loannidis V, Kuznetsov D, Liechti R, Moretti S, Mostaguir K, Redaschi N,
Rossier G, Xenarios I, Stockinger H: ExPASy: SIB bioinformatics resource
portal. Nucleic Acids Res 2012, 40:W597.
39. Bekmurzayeva A, Sypabekova M, Kanayeva D: Tuberculosis diagnosis using
immunodominant, secreted antigens of Mycobacterium tuberculosis.
Tuberculosis 2013, 93:381–388.
40. Lawn SD: Point-of-care detection of lipoarabinomannan (LAM) in urine
for diagnosis of HIV-associated tuberculosis: a state of the art review.
BMC Infect Dis 2012, 12:103.
41. Frenzel A, Fröde D, Meyer T, Schirrmann T, Hust M: Generating
Recombinant Antibodies for Research, Diagnostics and Therapy Using
Phage Display. Curr Biotechnol 2012, 1:33–41.
42. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A,
Wolle J, Plückthun A, Virnekas B: Fully synthetic human combinatorial
antibody libraries (HuCAL) based on modular consensus frameworks and
CDRs randomized with trinucleotides. J Mol Biol 2000, 296:57–86.
43. Loset GA, Lobersli I, Kavlie A, Stacy JE, Borgen T, Kausmally L, Hvattum E,
Simonsen B, Hovda MB, Brekke OH: Construction, evaluation and
refinement of a large human antibody phage library based on the IgD
and IgM variable gene repertoire. J Immunol Methods 2005, 299:47–62.
44. Schofield DJ, Pope AR, Clementel V, Buckell J, Chapple SD, Clarke KF,
Conquer JS, Crofts AM, Crowther SR, Dyson MR, Flack G, Griffin GJ, Hooks Y,
Fuchs et al. BMC Biotechnology 2014, 14:68 Page 16 of 16
http://www.biomedcentral.com/1472-6750/14/68Howat WJ, Kolb-Kokocinski A, Kunze S, Martin CD, Maslen GL, Mitchell JN,
O’Sullivan M, Perera RL, Roake W, Shadbolt SP, Vincent KJ, Warford A,
Wilson WE, Xie J, Young JL, McCafferty J: Application of phage display to
high throughput antibody generation and characterization. Genome Biol
2007, 8:R254.
45. Landowski CP, Godfrey HP, Bentley-Hibbert SI, Liu X, Huang Z, Sepulveda R,
Huygen K, Gennaro ML, Moy FH, Lesley SA, Haak-Frendscho M:
Combinatorial Use of Antibodies to Secreted Mycobacterial Proteins in a
Host Immune System-Independent Test for Tuberculosis. J Clin Microbiol
2001, 39:2418–2424.
46. Kremer L, Baulard A, Estaquier J, Poulain-Godefroy O, Locht C: Green
fluorescent protein as a new expression marker in mycobacteria.
Mol Microbiol 1995, 17:913–922.
47. Huygen K, Lozes E, Gilles B, Drowart A, Palfliet K, Jurion F, Roland I, Art M,
Dufaux M, Nyabenda J: Mapping of TH1 helper T-cell epitopes on major
secreted mycobacterial antigen 85A in mice infected with live
Mycobacterium bovis BCG. Infect Immun 1994, 62:363–370.
48. Launois P, DeLeys R, Niang MN, Drowart A, Andrien M, Dierckx P, Cartel JL,
Sarthou JL, Van Vooren JP, Huygen K: T-cell-epitope mapping of the major
secreted mycobacterial antigen Ag85A in tuberculosis and leprosy.
Infect Immun 1994, 62:3679–3687.
49. Roche PW, Peake PW, Billman-Jacobe H, Doran T, Britton WJ: T-cell
determinants and antibody binding sites on the major mycobacterial
secretory protein MPB59 of Mycobacterium bovis. Infect Immun 1994,
62:5319–5326.
50. Commandeur S, Lin MY, van Meijgaarden KE, Friggen AH, Franken KL,
Drijfhout JW, Korsvold GE, Oftung F, Geluk A, Ottenhoff TH: Double- and
monofunctional CD4(+) and CD8(+) T-cell responses to Mycobacterium
tuberculosis DosR antigens and peptides in long-term latently infected
individuals. Eur J Immunol 2011, 41:2925–2936.
51. Shen G, Behera D, Bhalla M, Nadas A, Laal S: Peptide-based antibody
detection for tuberculosis diagnosis. Clin Vaccine Immunol 2009, 16:49–54.
52. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: Basic local alignment
search tool. J Mol Biol 1990, 215:403–410.
53. Lightbody KA, Girvin RM, Pollock DA, Mackie DP, Neill SD, Pollock JM:
Recognition of a common mycobacterial T-cell epitope in MPB59 of
Mycobacterium bovis. Immunology 1998, 93:314–322.
54. Valle MT, Megiovanni AM, Merlo A, Li Pira G, Bottone L, Angelini G, Bracci L,
Lozzi L, Huygen K, Manca F: Epitope focus, clonal composition and Th1
phenotype of the human CD4 response to the secretory mycobacterial
antigen Ag85. Clin Exp Immunol 2001, 123:226–232.
55. D’Souza S, Rosseels V, Romano M, Tanghe A, Denis O, Jurion F, Castiglione N,
Vanonckelen A, Palfliet K, Huygen K: Mapping of murine Th1 helper T-Cell
epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from
Mycobacterium tuberculosis. Infect Immun 2003, 71:483–493.
56. Murphy K, Travers P, Walport M, Janeway C: Janeway’s immunobiology. 7th
edition. New York: Garland Science; 2008.
57. Arnon R: Enzyme inhibition by antibodies. Acta Endocrinol Suppl (Copenh)
1975, 194:133–153.
58. Mustafa AS, Abal AT, Shaban F, El-Shamy AM, Amoudy HA: HLA-DR binding
prediction and experimental evaluation of T-cell epitopes of mycolyl
transferase 85B (Ag85B), a major secreted antigen of Mycobacterium
tuberculosis. Med Princ Pract 2005, 14:140–146.
59. Gaseitsiwe S, Valentini D, Mahdavifar S, Magalhaes I, Hoft DF, Zerweck J,
Schutkowski M, Andersson J, Reilly M, Maeurer MJ: Pattern recognition in
pulmonary tuberculosis defined by high content peptide microarray
chip analysis representing 61 proteins from M. tuberculosis. PLoS One
2008, 3:e3840.
60. Nguyen YH, Ma X, Qin L: Rapid identification and drug susceptibility
screening of ESAT-6 secreting Mycobacteria by a NanoELIwell assay.
Sci Rep 2012, 2:635.
61. Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP,
Weiner LM, Marks JD: Expression of single-chain Fv-Fc fusions in Pichia
pastoris. J Immunol Methods 2001, 251:123–135.
62. Yin X, Zheng L, Lin L, Hu Y, Zheng F, Hu Y, Wang Q: Commercial
MPT64-based tests for rapid identification of Mycobacterium
tuberculosis complex: A meta-analysis. J Infect 2013, 67:369–377.
63. Ngamlert K, Sinthuwattanawibool C, McCarthy KD, Sohn H, Starks A,
Kanjanamongkolsiri P, Anek-vorapong R, Tasaneeyapan T, Monkongdee P,
Diem L, Varma JK: Diagnostic performance and costs of Capilia TB forMycobacterium tuberculosis complex identification from broth-based
culture in Bangkok, Thailand. Trop Med Int Health 2009, 14:748–753.
64. Geisbrecht BV, Nikonenko B, Samala R, Nakamura R, Nacy CA, Sacksteder KA:
Design and optimization of a recombinant system for large-scale
production of the MPT64 antigen from Mycobacterium tuberculosis.
Protein Expr Purif 2006, 46:64–72.
65. Chu TJ, Yuann JP: Expression, purification, and characterization of
protective MPT64 antigen protein and identification of its multimers
isolated from nontoxic Mycobacterium tuberculosis H37Ra. Biotechnol
Appl Biochem 2011, 58:185–189.
66. Oettinger T, Holm A, Haslov K: Characterization of the delayed type
hypersensitivity-inducing epitope of MPT64 from Mycobacterium
tuberculosis. Scand J Immunol 1997, 45:499–503.
67. Sambrook J, Russell D: Molecular Cloning: A Laboratory Manual. 3rd edition.
New York: Cold Spring Harbor Laboratory Press; 2001.
68. Schirrmann T, Hust M: Construction of human antibody gene libraries
and selection of antibodies by phage display. Methods Mol Biol 2010,
651:177–209.
69. Hust M, Steinwand M, Al-Halabi L, Helmsing S, Schirrmann T, Dübel S:
Improved microtitre plate production of single chain Fv fragments in
Escherichia coli. N Biotechnol 2009, 25:424–428.
70. Frank R: Spot-synthesis: an easy technique for the positionally
addressable, parallel chemical synthesis on a membrane support.
Tetrahedron 1992, 48:9217–9232.
71. Frank R: The SPOT-synthesis technique. Synthetic peptide arrays on
membrane supports–principles and applications. J Immunol Methods
2002, 267:13–26.
72. Frank R, Dübel S: Analysis of protein interactions with immobilized peptide
arrays synthesized on membrane supports. In Protein-Protein Interactions, A
Molecular Cloning Manual. 2nd edition. Edited by Golemis E, Adams PD. Cold
Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press; 2005.
73. Laemmli UK: Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature 1970, 227:680–685.
74. Schägger H, von Jagow G: Tricine-sodium dodecyl sulfate-polyacrylamide
gel electrophoresis for the separation of proteins in the range from 1 to
100 kDa. Anal Biochem 1987, 166:368–379.
75. Ronning DR, Vissa V, Besra GS, Belisle J, Sacchettini JC: Mycobacterium
tuberculosis Antigen 85A and 85C Structures Confirm Binding
Orientation and Conserved Substrate Specificity. J Biol Chem 2004,
279:36771–36777.
doi:10.1186/1472-6750-14-68
Cite this article as: Fuchs et al.: Novel human recombinant antibodies
against Mycobacterium tuberculosis antigen 85B. BMC Biotechnology
2014 14:68.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
